Kornimate/medical-research-clean huggingface dataset:
anesthetic optimization in pediatric lefort surgeries

Conditions: Le Fort; Pain, Postoperative

Summary: this study will propose and evaluate a standardized lefort osteotomy anesthetic protocol for pediatric patients at johns hopkins hospital. there are two cohorts to this study: a prospective cohort who will receive the study anesthesia protocol and a historical cohort that received standard of care. the investigators hope this will help to minimize unnecessary postoperative pain management, inpatient stay, and long-term morbidity and mortality in these patients.

this study will propose and evaluate a standardized lefort osteotomy anesthetic protocol for pediatric patients at johns hopkins hospital. there are two cohorts to this study: a prospective cohort who will receive the study anesthesia protocol and a historical cohort that received standard of care. the investigators hypothesize that implementation of this standardized protocol will show improved surgical outcomes among these patients as compared to current (discretionary) treatment. this study aims to optimize the anesthetic management of these patients in order to minimize postoperative pain management, inpatient stay, and long-term morbidity and mortality in these complex patients.

Eligibility criteria:
inclusion criteria: * undergoing le fort osteotomy at johns hopkins hospital * age \>= 14 years exclusion criteria: * contraindications to standardized anesthetic protocol (intervention arm)
post-marketing surveillance for crohn's disease participants treated with stelara (ustekinumab)

Conditions: Crohn Disease

Summary: the purpose of post-marketing surveillance (pms) is to assess the safety and effectiveness of ustekinumab (stelara) for crohn's disease participants under real world clinical practice.


Eligibility criteria:
inclusion criteria: * participants who are administered with stelara for the first time for the indication of crohn's disease in accordance with the label * participants must sign a participation agreement/informed consent form (icf) allowing data collection and source data verification in accordance with local requirements exclusion criteria: - have contraindication to stelara in accordance to the label
gemox in docetaxel-refractory castration-resistant prostate cancer

Conditions: Prostate Cancer

Summary: prostate cancer is one of the most common malignancies affecting men all over the world. metastatic prostate cancer responds to androgen deprivation for a variable period (20-25 months). prostate cancer that grows despite castrate levels of testosterone and that no longer responds to any form of hormonal manipulation is defined as castrate resistant prostate cancer (crpc). docetaxel combined with prednisolone has been shown to not only improve qol and psa response in crpc, but also extend the overall survival1. however, the efficacy of the drug has not been universally effective, and nearly all patients have disease progression after docetaxel treatment. after failure of a docetaxel regimen, with the exception of cabazitaxel or abiraterone, which are not widely and easily availabe in korea, little treatment regimen can be applied to the patients with reasonable response and benefits. gemcitabine is a nucleoside analog with activity against a broad spectrum of solid tumors. when gemcitabine is used as first-line therapy for crpc, disease control rate was 33% with median duration of 7.1 months. when it is combined with prednisone and zoledronic acid in pretreated patients with crpc, the psa response rate was 23% with a disease control rate of 57% in patients with measurable disease. oxaliplatin is newer platinum agent that has favorable toxicity profile and evidence of activity in cisplatin-resistant cell lines. droz et al. performed a multicenter phase ii study in 54 patients with metastatic crpc who were randomized to receive oxaliplatin either alone or with 5-fu. more than 50% of the patients had received prior chemotherapy including cisplatin. despite heavy pretreatment, psa desclines were noted in 11% and 19% of patients in each arm. gemcitabine plus oxaliplatin combination was widely studied and has been reported to be safe and effective in various cancers. this study is to assess the efficacy and safety of gemox in docetaxel-refractory crpc.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the prostate * clinical or radiologic evidence of metastatic disease * documented disease progression during hormone therapy (adt plus antiandrogen) and no response to adt withdrawal * docetaxel-refractory disease defined as disease progression documented either during treatment of within 60 days after the cessation of treatment with docetaxel * prior exposure to estramustine or mitoxantrone is allowed * kps ≥ 60 * no prior radioisotope therapy * no prior radiotherapy 25% or more of the bone marrow * no peripheral neuropathy grade 2 or worse * adequate organ and bone marrow function exclusion criteria: * other tumor type than adenocarcinoma * presence or history of cns metastasis * other serious illness or medical conditions

Keywords: castration-resistant prostate cancer docetaxel-refractory status
poor responders infertile patients -a great clinical challenge

Conditions: Invitro Fertilization

Summary: infertile , poor responders patients who underwent icsi. the participants were divided into 2 groups according to the starting dose of gn stimulation. group i started with 4 ampoules while group ii started with 6 ampoules

participants will be randomized to start induction with 4 or 6 ampoules of gonadotropins from day 2 till the day of human chorionic gonadotropin (hcg), dose adjusted according to ovarian response monitored by serum e2 and ultrasound evaluation. all patients were followed up by tvus scan daily or on alternate days according to the ovarian response to treatment starting on treatment cycle day 6 for folliculometry and endometrial thickness and pattern. cetrotide (merckserono, germany) 0.25 subcutaneously will be added when the leading follicle (df) reaches \>12 mm and hcg 10 000 iu intramuscularly (pregnyl, merck sharp, united kingdom)will be given only if we have at least 3 mature follicles \>14 mm and the leading one \>17 mm; then, ovum pickup (opu) was done after 36 hours of hcg and metaphase ii ocytes were analyzed. the intracytoplasmic sperm injection (icsi) procedure will be performed in all cases to avoid low fertilization rate by conventional ivf. fertilization was assessed 16 to 18 hours after icsi, and embryo quality will be evaluated 2 and 3 days after icsi according to the number of blastomeres and the degree of fragmentation and multinucleation. oocytes were collected and embryos will be cultured in ism1 culture medium (origiomedicult media, denmark). transfer of cleaving embryos will be done on day 3 after oocyte retrieval (using labotect semirigid catheter; labotect gmbh, germany), when the woman has at least 1 embryo (gi) otherwise canceled embryo transfer (et). the et was done by 1 person in each center. both of the transferring consultants have more than 5 years experience in ivf unit. . all patients will receive luteal support in the form of daily progesterone cyclogest (actavis, united kingdom) 800 mg daily starting from day of ovum retrieval till day of hcg testing. serum b hcg level was assessed on day 14 after et and considered positive if \>5 miu/ml. the tvus was performed 28 days after et to confirm ongoing pregnancy by visualization of intrauterine sac.

Eligibility criteria:
inclusion criteria: * poor responders according to "bologna consensus" with at least 2 of the following 3 points should be present: 1. age \>40 years or other cause of poor function. 2. afc\<2-5 in both ovaries or amh \< 0.5-1.1 ng/dl 2) 3. history of poor response with conventional stimulation protocol exclusion criteria: 1. uterine factor. 2. severe male factor. 3. endometriosis.
evaluation of effects of cbd products on anxiety among u.s. women

Conditions: Anxiety; Generalized Anxiety Disorder

Summary: the investigators will conduct a retrospective cohort analysis of a consumer trial conducted by rae wellness. the trial took place between october 15, 2020 and december 30, 2020 and involved 1350 u.s. women who used in-home use tests (ihut) of various cannabidiol (cbd) products. participants were randomized to one of 9 groups: 8 groups received one of 8 different cbd products in the mail, and one group served as the control and did not consume any cbd product. the cbd products varied by method of delivery, concentration of tetrahydrocannabinol (thc), and dosage of cbd. participants were asked to use the product once daily for 60 day and to complete health questionnaires at baseline, 30 days and 60 days.

between october 1-7, 2020, women from across the us were recruited by rae wellness to participate in a 60-day in-home use test (ihut) of various cannabidiol (cbd) products. the inclusion criteria were: women; between the ages of 24-44; reported symptoms associated with at least 4 out of 6 health issues (stress; anxiety; pain; sleep issues; digestive issues; low libido). individuals were excluded if they were pregnant or breastfeeding. 1,350 women were randomly selected to participate in the study. the participants were randomized to one of 9 groups in the ihut (150 in each group): 8 groups received one of 8 different cbd products in the mail, and one group served as the control and did not consume any cbd product. the cbd products varied by method of delivery (oil or capsule), concentration of tetrahydrocannabinol (thc; less than 0.3% thc or 0% thc), and dosage of cbd (15, 20, 25 and 30 mg). participants were asked to use the product once daily every day for 60 consecutive days, and to complete a health questionnaire online on 3 occasions: before initiating the product (baseline), 30 days after initiating the product, and 60 days after initiating the product. those in the control group were also asked to complete the health questionnaire at each time point but did not receive nor consume any cbd product. the health questionnaire assessed anxiety, physical health, digestive health, sleep patterns, general wellness and sexual satisfaction using questions drawn from validated health indices.

Eligibility criteria:
inclusion criteria: * self-identified female * ages of 24 to 44 years * reported symptoms associated with at least 4 out of 6 health issues (stress; anxiety; pain; sleep issues; digestive issues; low libido). exclusion criteria: -pregnant or breastfeeding

Keywords: cannabidiol tetrahydrocannabinol anxiety women
prevelance of frailty and its associated factors in patients with axial spondyloarthritis

Conditions: Frailty; Axial Spondyloarthritis

Summary: axial spondyloarthritis is an inflammatory arthritis disease and its main symptoms are chronic pain and stiffness, causing structural damage to the spinal vertebrae. axial spondyloarthritis leads to physical disability and a decrease in the level of physical activity. frailty is a syndrome characterized by decline in physiological reserve and loss of muscle strength. frailty can lead to vulnerability of individuals to possible injuries and a decrease in independence, and ultimately an increase in mortality. although frailty is associated with older adults, it has been reported that it can be detected in patients with cancer, diabetes and rheumatological diseases and it is not related with age. frailty has been reported to be a reversible and a treatable condition. the aim of our study was to investigate the prevalence of frailty and the relationship between frailty and disease activity, physical functional level, quality of life and other associated factors in individuals with axial spondyloarthritis.


Eligibility criteria:
inclusion criteria: * diagnosed with axial spondyloarthritis by an experienced rheumatologist. * to be between the ages of 40-65 exclusion criteria: * severe comorbidities such as cancer and stroke * being diagnosed with newly defined or recurrent cancer, * not having enough cognitive skills to answer the questions, * having neurological problems such as stroke * having cognitive impariment
hyaluronic acid filler imd1 basic for correction of nasolabial folds

Conditions: Nasolabial Folds

Summary: volunteers receive one injection imd1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.


Eligibility criteria:
inclusion criteria: * main inclusion criteria: severity rating scale grade 3 or 4 exclusion criteria: * main exclusion criterion: other nasolabial fold corrections within 6 months prior to study entry
clostridium difficile infection: the first report in southeast asia by 2010 nationwide study

Conditions: Clostridium Difficile Infection

Summary: the authors retrieved in-patient medical data, including the expense, from the 2010 thailand nationwide hospital admission database, which is part of the national health security office (nhso). the diagnosis of digestive diseases with any form of colitis listed in the causes, either as principal diagnosis or co-morbidity, coding by the icd-10 was recorded. the inclusion criteria were: 1) diagnosis of enterocolitis due to clostridium difficile (icd10-a07); and 2) age of more than 18 years. if the data was incomplete, the case was excluded. the baseline characteristics, including age, sex, co-morbidity disease and history of endoscopy or surgery, were recorded. the burden of cdi was evaluated by length of hospital stay (los), mortality rate, and hospital charge.


Eligibility criteria:
inclusion criteria: * the patients with the diagnosis of clostridium difficile (icd10-a07) * age of more than 18 years. exclusion criteria: * data incompleted

Keywords: clostridium difficile infection burden nationwide study south east asia thailand epidemiology outcome assessment (health care) [n04.761.559.590]
acceptance of complementary medicine in germany

Conditions: General Population

Summary: complementary medicine is widely practiced in germany and worldwide. the aim of this study is to explore how many people use complementary medicine methods in germany, for which health-related issues they do and for which they would not.


Eligibility criteria:
inclusion criteria: * informed consent * age at least 18 years * sufficient language skills as well as cognitive ability to participate in an online survey or interview lasting approximately 30 minutes * active consent to the online consent form exclusion criteria: - lack of consent to participate in the study
exploratory study of the safety, tolerability and efficacy of multiple regimens of natalizumab in adult participants with relapsing multiple sclerosis (ms)

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: the primary objective of this study is to explore the effects of multiple regimens of natalizumab on disease activity and safety in participants with relapsing-remitting multiple sclerosis (rrms).

this is a a dose and frequency (but not route of administration) blinded, prospective, randomized, dose-ranging study in patients with rrms who have received natalizumab for at least 12 months according to the local prescribing guidelines. the study will explore dosing of natalizumab by subcutaneous and intravenous routes. participants will be randomly assigned to 1 of 6 dosing regimens, blinded to natalizumab dose, but not route, for 60 weeks of treatment.

Eligibility criteria:
key inclusion criteria: * ability to provide written informed consent * subjects of childbearing potential must practice effective contraception during the study * a documented diagnosis of relapsing remitting multiple sclerosis (rrms) * free of ms relapse for 12 months prior to randomization * treatment with natalizumab for a minimum of 12 months immediately prior to randomization. * in the 12 months prior to commencing natalizumab, subject must have experienced a minimal level of disease activity as defined by 2 or more documented clinical relapses or 1 relapse and documented mri activity, defined by the presence of at least 1 gd enhancing lesion on mri, unrelated to the relapse. key exclusion criteria: * known history of human immunodeficiency virus (hiv), hepatitis c and/or hepatitis b virus * positive for anti-natalizumab antibodies at screening * mri positive for gd-enhancing lesions at study entry * subjects for whom mri is contraindicated * history of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic (including diabetes), urologic, pulmonary, neurologic (except for rrms), dermatologic, psychiatric, renal, or other major disease * history of malignant disease, including solid tumors and hematologic malignancies (with the exception of cured basal cell and squamous cell carcinomas of the skin) * history of transplantation or any anti-rejection therapy * history of severe allergic or anaphylactic reactions or known hypersensitivity to any drug * a clinically significant infectious illness within 30 days prior to screening or progressive multifocal leukoencephalopathy (pml) or other opportunistic infections at any time * signs or symptoms suggestive of any serious infection, based on medical history, physical examination or laboratory testing note: other protocol defined inclusion/exclusion criteria may apply.
to assess the impact of theeras consensus on patients with endoscopic pituitary tumor surgery

Conditions: Enhanced Recovery After Surgery; Pituitary Tumor; Postoperative Complications

Summary: the goal of this observational study is to evaluate the effectiveness and impact of enhanced recovery after surgery (eras) on patients with pituitary gland tumors.

the goal of this observational study is to evaluate the effectiveness and impact of enhanced recovery after surgery (eras) on patients with pituitary gland tumors. this study is particularly significant as eras has been a prominent focus in international medical treatment, emphasizing improved patient recovery and safety. the main questions it aims to answer are: how does eras affect the effectiveness and prognosis of patients with pituitary gland tumors? which specific inspection and evaluation items within the eras protocol genuinely assist patients? participants in this study will undergo various eras protocols, including pre-operative to post-operative rehabilitation measures, pain management, surgical techniques, and early resumption of eating and activities. this comprehensive approach is designed to reduce complications, shorten hospital stays, and speed up patient recovery. additionally, this study will conduct a thorough statistical analysis to determine which aspects of the eras protocol are most beneficial. by comparing the outcomes of patients undergoing the eras protocol with those who do not, researchers aim to understand better the balance between eras and the choosing wisely initiative, which advocates for reducing unnecessary medical interventions. this research is crucial in advancing medical knowledge and practice, particularly in managing pituitary gland tumors, and contributes to the broader goals of enhancing medical quality and patient safety.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pituitary tumors * to sign a written informed consent form exclusion criteria: * diagnosed with other malignant tumors * severe infections, such as osteomyelitis, acute inflammation at the affected site, or open wounds at the treatment area * pregnant women * coagulation disorders or those taking anticoagulant medication * other central nervous system disorders, alcohol addiction, other addictive drugs, or mental illness that may affect clinical assessment * deemed unsuitable for surgical treatment or unable to comply with clinical evaluation upon assessment

Keywords: enhanced recovery after surgery pituitary tumor anesthesia safety postoperative complications
isometric handgrip training on blood pressure of peripheral artery disease patients

Conditions: Peripheral Artery Disease

Summary: the aim of this study is to analyze the effects of isometric handgrip training (iht) on blood pressure of hypertensive patients with peripheral arterial disease. will be recruited 60 patients which will be randomized into 2 groups (30 per group), iht and control group (cg). iht group will training isometric contraction for 8 weeks. the gc patients will be encouraged to increase the level of physical activity. in the pre and post-intervention, brachial and central blood pressure will be measured.

meta-analyze studies have shown that iht promotes reductions in blood pressure (bp), reaching 10 mmhg for systolic and diastolic 7 mmhg. however, remain uncertain the effects of this type of training on bp in patients with more severe cardiovascular diseases such as peripheral artery disease. because this type of training which requires approximately 20 minutes per session and does not require supervision, it is possible that this intervention is interesting to reduce bp of these patients. the aim of this study is to analyze the effects of iht on blood pressure of hypertensive patients with peripheral arterial disease. will be recruited 60 patients, which will be randomized into 2 groups (30 per group), iht and control group (cg). iht group will hold three sessions per week with four unilateral sets with two minutes of isometric contraction at 30% of maximal voluntary contraction and interval of four minutes between them, for 8 weeks. the gc patients will be encouraged to increase the level of physical activity. in the pre and post-intervention, is going to be evaluated functional capacity, brachial and central bp, arterial stiffness, cardiovascular autonomic modulation and muscle vasodilation. will be used to analyze two-factor variance for repeated measures, with group (iht and gc) and the time (before and after 8 weeks) as factors and the post-hoc test of newman-keuls.

Eligibility criteria:
inclusion criteria: * postmenopausal without hormone therapy replacement, if woman; * present peripheral artery disease (ankle brachial index \< 0.90) in one or both lower limbs; * do not present neurological / cognitive diseases; * is able to practice home-based exercise; exclusion criteria: * patients will only be excluded if they make any medication changes before completing the intervention period or present any health problems that prevent physical activity.

Keywords: intermittent claudication exercise blood pressure cardiovascular system